Patent · US Active

Tropism modified cancer terminator virus (Ad.5/3 CTV;AD.5/3-CTV-M7)

US10314870B2 · kind B2 · utility

0Cited by

4References

14Claims

0Family size

Assignee

Virginia Commonwealth University · US

Inventors

Paul Fisher · Scarsdale, US
Devanand Sarkar · Richmond, US
Paul W. Dent · Stehag, SE

Key dates

Filing date	Dec 10, 2013
Grant date	Jun 11, 2019
Priority date	—
Expiry date	Dec 10, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/10371
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.